SMC approves first immunotherapy combination for advanced bowel cancer patients with rare mutation December 14, 2021 Auto Bot News 0 Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland for patients who have previously failed fluoropyrimidine-based chemotherapy.